{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:58:42Z","timestamp":1792756722998,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.drup.2022.100864","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T12:37:08Z","timestamp":1662467828000},"page":"100864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance"],"prefix":"10.1016","volume":"64","author":[{"given":"Mjriam","family":"Capula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Per\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dicky","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2022.100864_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5803-1","article-title":"Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells","volume":"19","author":"Amrutkar","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2012.00344","article-title":"Pancreatic stellate cells: a starring role in normal and diseased pancreas","volume":"3","author":"Apte","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.drup.2022.100864_bib3","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/j.gastro.2012.11.037","article-title":"A starring role for stellate cells in the pancreatic cancer microenvironment","volume":"144","author":"Apte","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2022.100864_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","article-title":"The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis","volume":"9","author":"Assaraf","year":"2006","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib6","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-13-0837","article-title":"Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma","volume":"73","author":"Avan","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ijc.28078","article-title":"Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back","volume":"133","author":"Avan","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1101\/gad.348523.121","article-title":"The biological underpinnings of therapeutic resistance in pancreatic cancer","volume":"35","author":"Beatty","year":"2021","journal-title":"Genes Dev."},{"key":"10.1016\/j.drup.2022.100864_bib9","article-title":"Microbiome definition re-visited: old concepts and new challenges","volume":"8","author":"Berg","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.drup.2022.100864_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1368-7646(02)00002-X","article-title":"Determinants of resistance to 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine)","volume":"5","author":"Bergman","year":"2002","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib11","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1073\/pnas.1918095117","article-title":"Targeted inhibition of gut bacterial \u03b2-glucuronidase activity enhances anticancer drug efficacy","volume":"117","author":"Bhatt","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2022.100864_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146987","article-title":"Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts","volume":"131","author":"Bhattacharjee","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2022.100864_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10555-014-9541-1","article-title":"The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal","volume":"34","author":"Bijlsma","year":"2015","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.drup.2022.100864_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","article-title":"Gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"23","author":"Binenbaum","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2021.03.006","article-title":"Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment","volume":"82","author":"Boyd","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2022.100864_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/bs.acr.2019.03.005","article-title":"Impact of the microbiome on cancer progression and response to anti-cancer therapies","volume":"143","author":"Buchta Rosean","year":"2019","journal-title":"Adv. Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib17","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1158\/1078-0432.CCR-17-2262","article-title":"Dual Inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer","volume":"24","author":"Camblin","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3892\/or.2015.3789","article-title":"HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer","volume":"33","author":"Cao","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2022.100864_bib19","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.3748\/wjg.v22.i31.6987","article-title":"FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer","volume":"22","author":"Caparello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drup.2022.100864_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv132","article-title":"Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma","volume":"107","author":"Capello","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2022.100864_bib21","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic Cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2019.02.006","article-title":"The double edge sword of fibrosis in cancer","volume":"209","author":"Chandler","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.drup.2022.100864_bib23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/gutjnl-2019-319807","article-title":"Therapeutic potential of microbial modulation in pancreatic cancer","volume":"70","author":"Chandra","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.drup.2022.100864_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/life12030327","article-title":"A review on the efficacy and safety of nab-paclitaxel with gemcitabine in combination with other therapeutic agents as new treatment strategies in pancreatic cancer","volume":"12","author":"Chapa-Gonz\u00e1lez","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.drup.2022.100864_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.drup.2022.100864_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12020286","article-title":"Potential role of exosomes in the chemoresistance to gemcitabine and nab-paclitaxel in pancreatic cancer","volume":"12","author":"Comandatore","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.drup.2022.100864_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drup.2017.07.001","article-title":"A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer","volume":"31","author":"Coppola","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.2019-0570","article-title":"Antibacterial use is associated with an increased risk of hematologic and gastrointestinal adverse events in patients treated with gemcitabine for stage IV pancreatic cancer","volume":"25","author":"Corty","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2022.100864_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","article-title":"Microbiome and cancer","volume":"39","author":"Cullin","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100864_bib30","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-19-0960","article-title":"Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance","volume":"79","author":"Dalin","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/14622416.10.1.69","article-title":"Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors","volume":"10","author":"Danesi","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.drup.2022.100864_bib32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-10-1855","article-title":"Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2","volume":"71","author":"Dangi-Garimella","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064566","article-title":"Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression","volume":"8","author":"Dangi-Garimella","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2022.100864_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41416-019-0683-3","article-title":"Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma","volume":"122","author":"De Jesus-Acosta","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41575-018-0013-x","article-title":"Microbiome promotes pancreatic cancer","volume":"15","author":"Dickson","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2022.100864_bib38","first-page":"16","article-title":"Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door","author":"Donadioa","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.drup.2022.100864_bib39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.15252\/emmm.201404346","article-title":"Pharmacological targeting of the protein synthesis mTOR\/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance","volume":"7","author":"Duluc","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.drup.2022.100864_bib40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17425255.2019.1620731","article-title":"Pharmacogenetics of treatments for pancreatic cancer","volume":"15","author":"El Hassouni","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drup.2022.100864_bib41","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.2174\/138161212800626175","article-title":"Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations","volume":"18","author":"Elnaggar","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drup.2022.100864_bib42","article-title":"Bacterial infections and cancer","volume":"19","author":"Elsland","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.drup.2022.100864_bib43","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2022.100864_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.immuni.2016.06.018","article-title":"Loss of the DNA damage repair kinase ATM impairs inflammasome-dependent anti-bacterial innate immunity","volume":"45","author":"Erttmann","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2022.100864_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2022.100864_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050638","article-title":"Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells","volume":"11","author":"Firuzi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100864_bib47","first-page":"714","article-title":"Mammalian dihydropyrimidine dehydrogenase","author":"Forouzesh","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.drup.2022.100864_bib48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","article-title":"The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?","volume":"28","author":"Frances","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2022.100864_bib49","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Disco"},{"key":"10.1016\/j.drup.2022.100864_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037424","article-title":"Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels","volume":"7","author":"Funamizu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2022.100864_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cell.2017.03.046","article-title":"Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics","volume":"169","author":"Garc\u00eda-Gonz\u00e1lez","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2022.100864_bib52","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.drup.2022.100864_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","article-title":"Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins","volume":"32","author":"Genovese","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41416-019-0509-3","article-title":"Cancer-associated fibroblasts-heroes or villains?","volume":"121","author":"Gieniec","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib55","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/17425255.2021.1948731","article-title":"Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems","volume":"17","author":"Giovannetti","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drup.2022.100864_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semcancer.2017.04.006","article-title":"Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer","volume":"44","author":"Giovannetti","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2022.100864_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccr.2014.05.026","article-title":"Pancreatic cancer stroma: friend or foe?","volume":"25","author":"Gore","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100864_bib58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2017.03.026","article-title":"Drug resistance in pancreatic cancer: Impact of altered energy metabolism","volume":"114","author":"Grasso","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2022.100864_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","volume":"106","author":"Greenhalf","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.drup.2022.100864_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2022.100864_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/00365521.2014.980318","article-title":"TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas","volume":"50","author":"Grunnet","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.drup.2022.100864_bib62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2021.08.029","article-title":"Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer","volume":"521","author":"Gu","year":"2021","journal-title":"Cancer Lett."},{"issue":"123","key":"10.1016\/j.drup.2022.100864_bib63","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41416-020-01029-7","article-title":"Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer \u2013 translational results from the AIO-PK0104 Phase 3 study","volume":"1239","author":"Guenther","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib64","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.4238\/2015.May.25.16","article-title":"Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model","volume":"14","author":"Gui","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.drup.2022.100864_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Disco"},{"key":"10.1016\/j.drup.2022.100864_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02022-5","article-title":"Cancer: a mirrored room between tumor bulk and tumor microenvironment","volume":"40","author":"Hern\u00e1ndez-Camarero","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib67","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","article-title":"TGF-\u03b2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3","volume":"37","author":"Hesler","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drup.2022.100864_bib68","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","article-title":"SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial","volume":"21","author":"Hidalgo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12038-015-9518-4","article-title":"Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice","volume":"40","author":"Hu","year":"2015","journal-title":"J. Biosci."},{"key":"10.1016\/j.drup.2022.100864_bib71","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/onc.2016.378","article-title":"TGF\u03b2 promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1","volume":"36","author":"Huang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2022.100864_bib72","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1665973","article-title":"Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients","volume":"8","author":"Huang","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drup.2022.100864_bib73","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-8-125","article-title":"Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines","volume":"8","author":"Huanwen","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib74","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Sciences"},{"key":"10.1016\/j.drup.2022.100864_bib75","article-title":"Correction: pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics","volume":"41","author":"Iida","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2022.100864_bib76","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1701326","article-title":"Antibiotics improve the treatment efficacy of oxaliplatin-based but not irinotecan-based therapy in advanced colorectal cancer patients","volume":"2020","author":"Imai","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib77","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.drup.2022.100864_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01553","article-title":"Probiotic strain lactobacillus casei BL23 prevents colitis-associated colorectal cancer","volume":"8","author":"Jacouton","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2022.100864_bib79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20517\/cdr.2018.02","article-title":"How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?","volume":"1","author":"Jaramillo","year":"2018","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.drup.2022.100864_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-62139-z","article-title":"Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment","volume":"10","author":"Kasper","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2022.100864_bib81","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1158\/0008-5472.CAN-05-3948","article-title":"TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer","volume":"66","author":"Kelly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib82","doi-asserted-by":"crossref","DOI":"10.1186\/s12934-020-01330-3","article-title":"Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma","volume":"19","author":"Kesh","year":"2020","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.drup.2022.100864_bib83","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib84","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-14-1269","article-title":"Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib85","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-15-0764","article-title":"SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts","volume":"15","author":"Kim","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2022.100864_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/biology10030219","article-title":"Microbiome markers of pancreatic cancer based on bacteria-derived extracellular vesicles acquired from blood samples: a retrospective propensity score matching analysis","volume":"10","author":"Kim","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.drup.2022.100864_bib87","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","article-title":"A phase I study of FOLFIRINOX Plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma","volume":"45","author":"Ko","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.drup.2022.100864_bib88","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14737159.2016.1175940","article-title":"Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment","volume":"16","author":"Le Large","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"5","key":"10.1016\/j.drup.2022.100864_bib89","first-page":"1","article-title":"Local bacteria affect the efficacy of chemotherapeutic drugs","volume":"51","author":"Lehouritis","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2022.100864_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100704","article-title":"Nanomedicine to target multidrug resistant tumors","volume":"52","author":"Lepeltier","year":"2020","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib91","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jnr.22029","article-title":"Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes","volume":"87","author":"Li","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.drup.2022.100864_bib92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100864_bib93","article-title":"The interplay between inflammation and stromal components in pancreatic cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2022.100864_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102262","article-title":"Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants","volume":"100","author":"Macchini","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2022.100864_bib95","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1158\/0008-5472.CAN-12-4601","article-title":"Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner","volume":"73","author":"Mace","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib96","first-page":"4349","article-title":"Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines","volume":"58","author":"Mackey","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib97","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-017-3388-4","article-title":"Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients","volume":"80","author":"Makihara","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.drup.2022.100864_bib98","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin. Cancer Res. . J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib99","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/SLA.0000000000003084","article-title":"Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma","volume":"271","author":"Meijer","year":"2020","journal-title":"Ann. Surg."},{"key":"10.1016\/j.drup.2022.100864_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102824","article-title":"Tumor microbiome: pancreatic cancer and duodenal fluids contain multitudes, \u2026but do they contradict themselves?","volume":"144","author":"Meijer","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2022.100864_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103571","article-title":"Evolving pancreatic cancer treatment: From diagnosis to healthcare management","volume":"169","author":"Milella","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2022.100864_bib102","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/bjc.2013.174","article-title":"Serum levels of IL-6 and IL-1\u03b2 can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer","volume":"108","author":"Mitsunaga","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib103","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09272-2","article-title":"Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I\/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma","volume":"22","author":"Mizutani","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib104","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","article-title":"Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis","volume":"79","author":"Mizutani","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib105","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1002\/cam4.3870","article-title":"Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients","volume":"10","author":"Mohindroo","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.drup.2022.100864_bib106","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3892\/or.2021.7924","article-title":"Catechol enhances chemo\u2011 and radio\u2011sensitivity by targeting AMPK\/Hippo signaling in pancreatic cancer cells","volume":"45","author":"Moon","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drup.2022.100864_bib107","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib108","first-page":"491","article-title":"The dark side of immunotherapy: pancreatic cancer","volume":"3","author":"Mucciolo","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.drup.2022.100864_bib109","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1073\/pnas.1300415110","article-title":"CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer","volume":"110","author":"Neesse","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2022.100864_bib110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/gutjnl-2013-305559","article-title":"SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice","volume":"63","author":"Neesse","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.drup.2022.100864_bib111","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drup.2022.100864_bib112","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-013-9439-3","article-title":"Stromal expression of SPARC in pancreatic adenocarcinoma","author":"Neuzillet","year":"2013","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.drup.2022.100864_bib113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.5224","article-title":"Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma","volume":"248","author":"Neuzillet","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.drup.2022.100864_bib114","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature19823","article-title":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","volume":"538","author":"Notta","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drup.2022.100864_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: an update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib116","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2022.100864_bib117","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drup.2022.100864_bib118","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100864_bib119","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdu157","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant","year":"2014","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100779","article-title":"GSK3\u03b2 as a novel promising target to overcome chemoresistance in pancreatic cancer","volume":"58","author":"Pecoraro","year":"2021","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib121","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1099\/mic.0.000149","article-title":"Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice","volume":"161","author":"Pedroso","year":"2015","journal-title":"Microbiology"},{"key":"10.1016\/j.drup.2022.100864_bib122","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0163-7258(00)00086-3","article-title":"Basis for effective combination cancer chemotherapy with antimetabolites","volume":"87","author":"Peters","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drup.2022.100864_bib123","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","article-title":"Fluorouracil: biochemistry and pharmacology","volume":"6","author":"Pinedo","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib124","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2095-1","article-title":"Microbiome analyses of blood and tissues suggest cancer diagnostic approach","volume":"579","author":"Poore","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2022.100864_bib125","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.2013.51.0826","article-title":"Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity","volume":"31","author":"Poplin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib126","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pan.2020.01.003","article-title":"Pancreatic stellate cells: aiding and abetting pancreatic cancer progression","volume":"20","author":"Pothula","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.drup.2022.100864_bib127","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2022.100864_bib128","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100864_bib129","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrmicro2539","article-title":"Modulation of NF-\u03baB signalling by microbial pathogens","volume":"9","author":"Rahman","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.drup.2022.100864_bib130","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113206","article-title":"Open sesame?: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer","volume":"12","author":"Randazzo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100864_bib132","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100864_bib133","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/onc.2016.353","article-title":"Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells","volume":"36","author":"Richards","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2022.100864_bib134","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drup.2022.100864_bib135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.795735","article-title":"Deconstructing pancreatic cancer using next generation-omic technologies-from discovery to knowledge-guided platforms for better patient management","volume":"9","author":"Schreyer","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2022.100864_bib137","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Sepich-Poore","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drup.2022.100864_bib138","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.drup.2022.100864_bib139","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ejca.2015.05.005","article-title":"Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial","volume":"51","author":"Sinn","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2022.100864_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/nu13124425","article-title":"Pancreatic cancer and gut microbiome-related aspects: a comprehensive review and dietary recommendations","volume":"13","author":"Sobocki","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.drup.2022.100864_bib141","first-page":"58","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","author":"Su","year":"2021","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib142","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.3748\/wjg.v18.i35.4944","article-title":"Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?","volume":"18","author":"Sun","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.drup.2022.100864_bib143","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0006-291X(92)90634-W","article-title":"Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA\/PCR-based quantitation assay","volume":"184","author":"Takeda","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2022.100864_bib144","first-page":"2096","article-title":"Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer","volume":"8","author":"Tezuka","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib145","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","article-title":"Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes","volume":"71","author":"Ting","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.drup.2022.100864_bib146","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.syapm.2012.03.004","article-title":"CLASI-FISH: principles of combinatorial labeling and spectral imaging","volume":"35","author":"Valm","year":"2012","journal-title":"Syst. Appl. Microbiol."},{"key":"10.1016\/j.drup.2022.100864_bib147","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib148","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.fob.2015.07.007","article-title":"Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs","volume":"5","author":"Vande Voorde","year":"2015","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.drup.2022.100864_bib149","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1099\/jmm.0.000292","article-title":"5-Fluorouracil sensitivity varies among oral micro-organisms","volume":"65","author":"Vanlancker","year":"2016","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.drup.2022.100864_bib150","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10968-6","article-title":"CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan","volume":"10","author":"Vennin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2022.100864_bib151","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib152","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-017-0448-5","article-title":"The role of stromal cancer-associated fibroblasts in pancreatic cancer","volume":"10","author":"Von Ahrens","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2022.100864_bib153","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2022.100864_bib154","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1126\/science.1191175","article-title":"Alleviating cancer drug toxicity by inhibiting a bacterial enzyme","volume":"330","author":"Wallace","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.drup.2022.100864_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib156","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","article-title":"Genetically engineered mouse models of pancreatic cancer","volume":"18","author":"Westphalen","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.drup.2022.100864_bib157","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-017-0608-3","article-title":"Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20","volume":"19","author":"Wong","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.drup.2022.100864_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100833","article-title":"The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells","volume":"62","author":"Xavier","year":"2022","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2022.100864_bib159","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2016.11.006","article-title":"Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-\u03b21\/Gfi-1 axis","volume":"385","author":"Xian","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2022.100864_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118523","article-title":"Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met\/PI3K\/Akt signaling in pancreatic cancer in vitro","volume":"263","author":"Xu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.drup.2022.100864_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.851512","article-title":"c-Myc-PD-L1 axis sustained gemcitabine-resistance in pancreatic cancer","volume":"13","author":"Yao","year":"2022","journal-title":"Front. Pharm."},{"key":"10.1016\/j.drup.2022.100864_bib162","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2022.100864_bib163","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopha.2018.08.165","article-title":"The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer","volume":"108","author":"Yuan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drup.2022.100864_bib164","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01693-15","article-title":"Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces","volume":"6","author":"Zaura","year":"2015","journal-title":"MBio"},{"issue":"85","key":"10.1016\/j.drup.2022.100864_bib165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/prd.12359","article-title":"Optimizing the quality of clinical studies on oral microbiome: a practical guide for planning, performing, and reporting","volume":"2000","author":"Zaura","year":"2021","journal-title":"Periodontol"},{"key":"10.1016\/j.drup.2022.100864_bib166","first-page":"20","article-title":"Chemoresistance in pancreatic cancer","author":"Zeng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2022.100864_bib167","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2217\/fmb.09.62","article-title":"Multicomponent drug efflux complexes: architecture and mechanism of assembly","volume":"4","author":"Zgurskaya","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.drup.2022.100864_bib168","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-17-1366","article-title":"Tumor-stroma IL1\u03b2-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100864_bib169","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.18632\/oncotarget.3099","article-title":"Paracrine SDF-1\u03b1 signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100864_bib170","first-page":"14","article-title":"Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3","volume":"38","author":"Zhang","year":"2019","journal-title":"Expr. Colorectal Cancer. J. Exp. Clin. Cancer Res."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764622000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764622000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:01:09Z","timestamp":1761282069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764622000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":170,"alternative-id":["S1368764622000632"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2022.100864","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2022.100864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100864"}}